<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624659</url>
  </required_header>
  <id_info>
    <org_study_id>4202-HEM-301</org_study_id>
    <nct_id>NCT04624659</nct_id>
  </id_info>
  <brief_title>A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)</brief_title>
  <official_title>An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forma Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forma Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of&#xD;
      FT-4202 and test how well FT-4202 works compared to placebo to improve the amount of&#xD;
      hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the&#xD;
      blood vessels become blocked and cause pain).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FT-4202 is designed to activate PKR and thereby modulate RBC metabolism by impacting two&#xD;
      critical pathways in RBCs. The FT-4202 clinical development program will investigate whether&#xD;
      decreasing 2,3-DPG may help oxygen bind to hemoglobin (i.e. increasing oxygen affinity), and&#xD;
      thereby increase ATP and impact RBC function. This study is a randomized, placebo-controlled,&#xD;
      double-blind, multicenter Phase 2/3 study of patients age 12 to 65 years (inclusive), with&#xD;
      sickle cell disease. There are two planned interim analyses in this study design. Initially,&#xD;
      patients will be randomized at 1:1:1 to one of two dose levels of FT-4202 or placebo. At the&#xD;
      first interim analysis, one of the two FT-4202 dose levels will be selected for the Phase 3&#xD;
      portion of the study, in which patients will be randomized at 1:1 to the selected FT-4202&#xD;
      dose or placebo. Efficacy on hemoglobin will be evaluated at the second interim analysis, and&#xD;
      then will be tested along with evaluation of efficacy on vaso-occlusive crises at the final&#xD;
      analysis. Following completion of 52 weeks of double-blind treatment, patients may enter a&#xD;
      52-week FT-4202 open-label extension period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin response rate at Week 24 (increase of &gt; 1 g/dL [&gt; 10 g/L] from baseline) during the blinded treatment period</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized vaso-occlusive crisis rate during the 52-week blinded treatment period based on adjudicated vaso-occlusive crisis review</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin at Week 24 during the blinded treatment period</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sickle Cell Disease related clinical laboratory measurements from baseline at Week 24 during the blinded treatment period</measure>
    <time_frame>24 Weeks</time_frame>
    <description>% reticulocytes,&#xD;
Unconjugated bilirubin&#xD;
Lactate dehydrogenase (LDH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first vaso-occlusive during the blinded treatment period</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Scale at Week 24 during the blinded treatment period</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Adult patients (ages 18 to 65) will complete the PROMIS® Item Bank v.1.0 - Fatigue - Short Form 7a. Adolescent patients (ages 12 to 17) will complete the PROMIS® Item Bank v2.0 - Fatigue - Short Form 10a. Responses are graded on a score of 1 to 5 with a higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Double blind FT-4202 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double blind FT-4202 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Blind Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open label FT-4202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT-4202 Tablets</intervention_name>
    <description>200 mg once daily</description>
    <arm_group_label>Double blind FT-4202 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT-4202 Tablets</intervention_name>
    <description>400 mg once daily</description>
    <arm_group_label>Double blind FT-4202 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Placebo once daily</description>
    <arm_group_label>Double Blind Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT-4202 Tablets</intervention_name>
    <description>Selected dose once daily</description>
    <arm_group_label>Open label FT-4202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of consent&#xD;
&#xD;
          -  Patient has a confirmed diagnosis of sickle cell disease&#xD;
&#xD;
          -  At least 2 episodes of vaso-occlusive crises in the past 12 months&#xD;
&#xD;
          -  Hemoglobin ≥ 5.5 and ≤ 10 g/dL (≥ 55 and ≤ 100 g/L) during screening&#xD;
&#xD;
          -  Patients taking hydroxyurea, must demonstrate a stable dose for at least 90 days prior&#xD;
             to start of study treatment&#xD;
&#xD;
          -  Female patients of childbearing potential must use highly effective methods of&#xD;
             contraception, male patients are willing to use barrier methods of contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          -  More than 10 vaso-occlusive crises within the past 12 months&#xD;
&#xD;
          -  Female who is breast feeding or pregnant&#xD;
&#xD;
          -  Hepatic dysfunction characterized by:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 4.0 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Direct bilirubin &gt; 3.0 × ULN&#xD;
&#xD;
          -  Known HIV positive&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Severe renal dysfunction or on chronic dialysis&#xD;
&#xD;
          -  History of unstable or deteriorating cardiac or pulmonary disease within 6 months&#xD;
             prior to consent including but not limited to the following:&#xD;
&#xD;
               -  Unstable angina pectoris or myocardial infarction or elective coronary&#xD;
                  intervention&#xD;
&#xD;
               -  Congestive heart failure requiring hospitalization&#xD;
&#xD;
               -  Uncontrolled clinically significant arrhythmias&#xD;
&#xD;
               -  Symptomatic pulmonary hypertension&#xD;
&#xD;
          -  History of overt clinical stroke within previous 2 years or any history of an&#xD;
             intracranial hemorrhage&#xD;
&#xD;
        Prior/Concomitant Therapy&#xD;
&#xD;
          -  Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed&#xD;
             chronic, prophylactic, or preventive transfusion)&#xD;
&#xD;
          -  Receiving or use of concomitant medications that are strong inducers or&#xD;
             moderate/strong inhibitors of CYP3A4/5 within 2 weeks of starting study treatment or&#xD;
             anticipated need for such agents during the study&#xD;
&#xD;
          -  Use of voxelotor within 28 days prior to starting study treatment or anticipated need&#xD;
             for this agent during the study&#xD;
&#xD;
          -  Use of a selectin antagonist (eg, crizanlizumab or other monoclonal antibody or small&#xD;
             molecule) within 28 days of starting study treatment or anticipated need for such&#xD;
             agents during the study&#xD;
&#xD;
          -  Use of erythropoietin or other hematopoietic growth factor treatment within 28 days of&#xD;
             starting study treatment or anticipated need for such agents during the study&#xD;
&#xD;
          -  Receipt of prior cellular-based therapy (eg, hematopoietic cell transplant, gene&#xD;
             modification therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vandy Black, MD</last_name>
    <role>Study Director</role>
    <affiliation>Forma Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Forma Therapeutics, Inc.</last_name>
    <phone>617-679-1970</phone>
    <email>clinicaltrials@formatherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Warner</last_name>
      <phone>205-996-5530</phone>
      <email>ewarner@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Sieber</last_name>
      <phone>602-933-7007</phone>
      <email>esieber@phoenixchildrens.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tandi Ilsom</last_name>
      <phone>501-221-8681</phone>
      <email>tilsom@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research, LLC.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Caruso</last_name>
      <phone>916-933-3023</phone>
      <email>jeanette@alliancesites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Flores</last_name>
      <phone>510-444-2877</phone>
      <email>jamieflores@pacifictrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center - UC Davis Comprehensive Cancer Center - Hemotology/Oncology Clinic</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Gam</last_name>
      <phone>800-362-5566</phone>
      <email>sgam@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Connecticut (UCONN) Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Green</last_name>
      <phone>860-679-8199</phone>
      <email>zgreen@uchc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Igwe</last_name>
      <phone>202-865-6498</phone>
      <email>Raliat.igwe@howard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornerstone Research Institute</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derrica Robinson</last_name>
      <phone>407-257-8102</phone>
      <email>drobinson@cornerstonestudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foundation for Sickle Cell Disease Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanetta Bronte-Hall, MD</last_name>
      <phone>954-397-3251</phone>
      <email>lbronte@fscdr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR LLC.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivette Lopez</last_name>
      <phone>305-220-2727</phone>
      <phone_ext>805</phone_ext>
      <email>ilopez@advancedpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sonar Clinical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chikita Cunningham</last_name>
      <phone>317-332-5378</phone>
      <email>chikitacunningham@comcast.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Pediatric Research Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chavon Porter</last_name>
      <phone>404-785-8863</phone>
      <email>chavon.porter@choa.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois College of Medicine (UICM) - Chicago - Outpatient Care Center (OCC) - Pediatric Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lani Krauz</last_name>
      <phone>312-996-7714</phone>
      <email>lignacio@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Smith</last_name>
      <phone>410-328-0687</phone>
      <email>nancysmith@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Pottier</last_name>
      <phone>617-638-7480</phone>
      <email>elizabeth.pottier@bmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Tolksdorf</last_name>
      <phone>313-576-8673</phone>
      <email>tolksdoe@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Barnes - Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sierra Shockley</last_name>
      <phone>314-747-8855</phone>
      <email>shockley.sierra@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Gaines</last_name>
      <phone>402-559-3848</phone>
      <email>serena.gaines@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Diaz</last_name>
      <phone>718-918-4284</phone>
      <email>olga.diaz@nychhc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ireland</last_name>
      <phone>718-741-2342</phone>
      <email>kireland@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings County Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Chrispi</last_name>
      <phone>718-245-3131</phone>
      <email>chrispid@nychhc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queens Hospital Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Bulone</last_name>
      <phone>718-883-3000</phone>
      <email>bulonel@nychhc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colombia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Manrique</last_name>
      <phone>212-305-5371</phone>
      <email>Dm3489@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wichlan</last_name>
      <phone>919-966-2898</phone>
      <email>dwichlan@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University - Sickle Cell Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Muller</last_name>
      <phone>919-684-5378</phone>
      <email>lindsey.muller@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research</name>
      <address>
        <city>North Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Boyce</last_name>
      <phone>330-493-1118</phone>
      <email>lboyce@nb-cr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Schwab</last_name>
      <phone>918-289-0083</phone>
      <email>lschwab@lhsi.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tranaka Fuqua</last_name>
      <phone>543-720-5665</phone>
      <email>tranaka.fuqua@prismahealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard HERRIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salima Merazga</last_name>
      <phone>+33 4 72 11 03 41</phone>
      <email>salima.merazga@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital De Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saioa Arambarri</last_name>
      <phone>34677380668</phone>
      <email>saioa.arambarriurunuela@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rojo</last_name>
      <phone>34 91 497 2418</phone>
      <email>laurarojohematologia@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Sickle Cell</keyword>
  <keyword>Anemia</keyword>
  <keyword>Sickle Cell Anemia</keyword>
  <keyword>Hemolytic</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Vaso-occlusive Crisis</keyword>
  <keyword>Sickle Cell Crisis</keyword>
  <keyword>Congenital Anemia</keyword>
  <keyword>Hemolytic Anemia</keyword>
  <keyword>Hematologic Disease</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <keyword>Genetic Disease</keyword>
  <keyword>Inborn Disease</keyword>
  <keyword>Sickle Cell Trait</keyword>
  <keyword>Pyruvate Kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

